Future directions for checkpoint inhibition in melanoma.
作者信息
Hamid Omid
机构信息
The Angeles Clinic and Research Institute, Los Angeles, California.
出版信息
Clin Adv Hematol Oncol. 2016 Feb;14(2):85-6.
PMID:27057805
Abstract
摘要
相似文献
1
Future directions for checkpoint inhibition in melanoma.
Clin Adv Hematol Oncol. 2016 Feb;14(2):85-6.
2
Checkpoint Immunotherapy: Picking a Winner.
Cancer Discov. 2016 Aug;6(8):818-20. doi: 10.1158/2159-8290.CD-16-0694.
3
Checkpoint inhibitors in breast cancer: hype or promise?
Clin Adv Hematol Oncol. 2016 Jun;14(6):392-5.
4
Immune Checkpoint Therapy in Melanoma.
Cancer J. 2016 Mar-Apr;22(2):73-80. doi: 10.1097/PPO.0000000000000183.
5
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
Semin Cancer Biol. 2019 Dec;59:290-297. doi: 10.1016/j.semcancer.2019.08.001. Epub 2019 Aug 17.
6
Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
Future Oncol. 2016 Feb;12(4):551-64. doi: 10.2217/fon.15.309. Epub 2016 Jan 18.
7
The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
Cancer J. 2016 Mar-Apr;22(2):96-100. doi: 10.1097/PPO.0000000000000175.
8
Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies.
EBioMedicine. 2016 Nov;13:1-2. doi: 10.1016/j.ebiom.2016.11.014. Epub 2016 Nov 11.
9
Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?
Future Oncol. 2017 Feb;13(5):381-383. doi: 10.2217/fon-2016-0462. Epub 2016 Nov 25.
10
Clinical use of checkpoint inhibition in kidney cancer.
Clin Adv Hematol Oncol. 2016 Jun;14(6):427-9.
Zotero 插件